Rhumbline Advisers Has $568,000 Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Rhumbline Advisers grew its position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 18.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 68,053 shares of the company’s stock after purchasing an additional 10,573 shares during the quarter. Rhumbline Advisers owned approximately 0.13% of Zevra Therapeutics worth $568,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in ZVRA. Vestal Point Capital LP bought a new stake in Zevra Therapeutics during the 3rd quarter worth approximately $3,644,000. Geode Capital Management LLC grew its stake in shares of Zevra Therapeutics by 14.2% in the third quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock worth $7,246,000 after purchasing an additional 129,600 shares during the last quarter. Barclays PLC increased its holdings in Zevra Therapeutics by 292.6% in the third quarter. Barclays PLC now owns 57,599 shares of the company’s stock valued at $399,000 after purchasing an additional 42,926 shares during the period. Propel Bio Management LLC bought a new position in Zevra Therapeutics during the 3rd quarter worth $1,248,000. Finally, Simplify Asset Management Inc. acquired a new position in Zevra Therapeutics during the 3rd quarter worth about $833,000. 35.03% of the stock is currently owned by institutional investors.

Zevra Therapeutics Price Performance

Zevra Therapeutics stock opened at $8.10 on Friday. The stock’s 50 day moving average price is $7.97 and its two-hundred day moving average price is $8.13. The stock has a market capitalization of $432.35 million, a price-to-earnings ratio of -4.11 and a beta of 1.98. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. Zevra Therapeutics, Inc. has a 52-week low of $4.20 and a 52-week high of $9.76.

Insider Buying and Selling

In related news, CEO Neil F. Mcfarlane sold 61,273 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $481,605.78. Following the transaction, the chief executive officer now directly owns 222,060 shares of the company’s stock, valued at approximately $1,745,391.60. This represents a 21.63 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO R. Laduane Clifton sold 11,000 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $86,460.00. Following the completion of the transaction, the chief financial officer now owns 51,361 shares in the company, valued at approximately $403,697.46. The trade was a 17.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 85,773 shares of company stock valued at $674,176 over the last ninety days. 2.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ZVRA. Cantor Fitzgerald raised Zevra Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 29th. Canaccord Genuity Group decreased their target price on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. Finally, Guggenheim set a $21.00 price objective on shares of Zevra Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, February 4th. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $21.71.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.